Abstract:
Low-grade myofibroblastic sarcoma (LGMS) characterized by the increased proliferation of myofibroblasts is a rare type of malignant myofibroblastic tumor that frequently occurs in the head and neck region. Presently, there is no consensus regarding the treatment of LGMS. Here, we report a rare case of LGMS of the pharynx in a 40-year-old male admitted to our hospital. The patient underwent resection for a right metastatic lesion and parapharyngeal mass. However, he had recurrence and multiple metastases without a surgical indication. Then the patient received the treatment of anlotinib plus pembrolizumab for 4 cycles, and there was a partial response (PR) to the treatment. Due to the adverse reaction of anlotinib, the patient subsequently received monotherapy of pembrolizumab for 22 cycles and achieved a complete response (CR). As the first case report of the immunotherapy for LGMS, our study highlights that this strategy may be of great significance to the treatment of LGMS.
摘要:
以成纤维细胞增殖增加为特征的低度肌纤维母细胞肉瘤(LGMS)是一种罕见的恶性肌纤维母细胞瘤,经常发生在头颈部。目前,关于LGMS的治疗尚无共识。这里,我们报告了一例罕见的咽部LGMS病例,其中一名40岁男性入院.患者接受了右转移性病变和咽旁肿块的切除术。然而,他有复发和多发转移,没有手术指征。然后患者接受安洛替尼联合派姆单抗治疗4个周期,对治疗有部分反应(PR)。由于安洛替尼的不良反应,患者随后接受了22个周期的派博利珠单抗单药治疗,达到完全缓解(CR).作为LGMS免疫治疗的首例病例报告,我们的研究强调这一策略可能对LGMS的治疗具有重要意义.